Non-small-cell lung cancer and breast carcinoma: chemotherapy and beyond

Lancet Oncology

Volumn 7, Issue 5, 2006, Pages 416-424

  Dubey, Sarita ^a   Siegfried, Jill M ^b   Traynor, Anne M ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ESTROGEN; ETOPOSIDE; EXEMESTANE; FLUOROURACIL; GEFITINIB; GEMCITABINE; LAPATINIB; METHOTREXATE; NAVELBINE; PACLITAXEL; PEMETREXED; TAMOXIFEN; TOBACCO SMOKE; TRASTUZUMAB; UFT; UNINDEXED DRUG; VINBLASTINE; VINDESINE;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; HUMAN; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MASTECTOMY; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SMOKING; SYSTEMATIC REVIEW; SYSTEMIC THERAPY;

ADJUVANTS, PHARMACEUTIC; BREAST NEOPLASMS; CARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; DRUG THERAPY; FEMALE; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 33646119175     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(06)70693-3     Document Type: Review

References (82)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. National Cancer Institute. Surveillance epidemiology and end results: cancer of the breast. Seer cancer statistics review 1975-2002. http://seer.cancer.gov/statfacts/html/breast.html?statfacts_page=breast. html&x=10&y=18 (accessed April 10, 2006)
3. National Cancer Institute. Surveillance epidemiology and end results: cancer of the lung and bronchus. http://seer.cancer.gov/statfacts/html/lungb.html?statfacts_page=lungb.ht ml&x=11&y=17 (accessed April 10, 2006)
4. Fisher B., Jeong J., Anderson S., et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 347 (2002) 567-575
5. Bonadonna G., Brusamolino E., Valagussa P., et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294 (1976) 405-410
6. Bonadonna G., Valagussa P., Moliterni A., et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 332 (1995) 901-906
7. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352 (1998) 930-942
8. Mansour E., Gray R., Shatila A., et al. Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis-an intergroup study. J Clin Oncol 16 (1998) 3486-3492
9. Citron M., Berry D., Cirrincione C., et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21 (2003) 1431-1439
10. PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 352 (1998) 257-263
11. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311 (1995) 899-909
12. Arriagada R., Bergman B., Dunant A., et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 (2004) 351-360
13. Kato H., Ichinose Y., Ohta M., et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350 (2004) 1713-1721
14. Winton T., Livingston R., Johnson D., et al. Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer. N Engl J Med 352 (2005) 2589-2597
15. Strauss G., Herndon J., Maddaus M., et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) Protocol 9633. Proc Am Soc Clin Oncol 23 (2004) abstr 7019
16. Douillard J., Rosell R., Delena M., et al., on behalf of the Adjuvant Navelbine International Trialist Association. Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): final results after 70-month median follow-up. Proc Am Soc Clin Oncol 24 (2005) abstr 7013
17. Esteva F., Valero V., Pusztai L., et al. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 6 (2001) 133-146
18. Hortobagyi G., Gutterman J., Blumenschein G., et al. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. Cancer 43 (1979) 1225-1233
19. Biganzoli L., Cufer T., Bruning P., et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol 20 (2002) 3114-3121
20. Extra J., Cognetti F., Maraninchi D., et al. Long-term survival demonstrated with trastuzumab plus docetaxel: 24-month data from a randomised trial (M77001) in HER2-positive metastatic breast cancer. Proc Am Soc Clin Oncol 24 (2005) abstr 555
21. O'Shaughnessy J., Miles D., Vukelja S., et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20 (2002) 2812-2823
22. Schiller J., Harrington D., Belani C., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
23. Fossella F., Pereira J., von Pawel J., et al., on behalf of the TAX 326 study group. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 21 (2003) 3016-3024
24. Sandler A., Gray R., Brahmer J., et al., on behalf of the Eastern Cooperative Oncology Group. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Oncology Cooperative Oncology Group (ECOG) trial-E4599. Proc Am Soc Clin Oncol 24 (2005) abstr LBA4
25. Hanna N., Shepherd F., Fossella F., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 (2004) 1589-1597
26. Shepherd F., Rodrigues Pereira J., Ciuleanu T., et al., on behalf of the National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
27. Vogel C., Cobleigh M., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20 (2002) 719-726
28. Cappuzzo F., Hirsch F., Rossi E., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97 (2005) 643-655
29. Pao W., Zakowski M., Cordon-Cardo C., et al. Molecular characteristics of non-small cell lung cancer (NSCLC) patients sensitive to gefitinib. Proc Am Soc Clin Oncol 23 (2004) abstr 7025
30. Tsao M., Sakurada A., Cutz J., et al. Erlotinib in lung cancer: molecular and clinical predictors of outcome. N Engl J Med 353 (2005) 133-144
31. Pegram M., Lopez A., Konecny G., and Slamon D. Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol 27 suppl 11 (2000) 21-25
32. Pietras R., Fendly B., Chazin V., et al. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9 (1994) 1829-1838
33. Aboud-Pirak E., Hurwitz E., Pirak M., et al. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 80 (1988) 1605-1611
34. Sirotnak F., Zakowiski M., Miller V., et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6 (2000) 4885-4892
35. Gatzemeier U., Pluzanska A., Szczesna A., et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 23 (2004) abstr 7010
36. Thienelt C., Bunn Jr. P., Hanna N., et al. Multicentered phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small cell lung cancer. J Clin Oncol 23 (2005) 8786-8793
37. Rosell R., Daniel C., Ramlau R., et al. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 23 (2004) abstr 618
38. Patel J., Bach P., and Kris M. Lung cancer in US women: a contemporary epidemic. JAMA 291 (2004) 1763-1768
39. Kuiper G., Carlsson B., Grandien K., et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138 (1997) 863-869
40. Mosselman S., Polman J., and Dijkema R. ERβ: identification and characterization of a novel estrogen receptor. FEBS Lett 392 (1996) 49-53
41. Patrone C., Cassel T., Petterssoh K., et al. Regulation of postnatal lung development and homeostasis by estrogen receptor β. Mol Cell Biol 23 (2003) 8542-8552
42. Kaiser U., Hofmann J., Schilli M., et al. Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. Int J Cancer 67 (1996) 357-364
43. Mollerup S., Jorgensen K., Berge G., et al. Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer 37 (2002) 153-159
44. Fasco M., Hurteau G., and Spivack S. Gender-dependent expression of alpha and beta estrogen receptors in human non-tumor and tumor lung tissue. Mol Cell Endocrinol 188 (2002) 125-140
45. Su J., Hsu H., Chang H., et al. Expression of estrogen and progesterone receptors in non-small cell lung cancer: immunochemical study. Anticancer Res 16 (1996) 3803-3806
46. Stabile L., Davis A., Gubish C., et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor α and β and show biological responses to estrogen. Cancer Res 62 (2002) 2141-2150
47. Omoto Y., Kobayashi Y., Nishida K., et al. Expression, function, and clinical implications of the estrogen receptor β in human lung cancers. Biochem Biophys Res Commun 285 (2001) 340-347
48. Pietras R., Marquez D., Chen H., et al. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids 70 (2005) 372-381
49. Stabile L., Lyker J., Gubish C., et al. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 65 (2005) 1459-1470
50. Hershberger P., Vasquez A., Kanterewicz B., et al. Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. Cancer Res 65 (2005) 1598-1605
51. Taioli E., and Wynder E. Re: Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst 86 (1994) 869-870
52. Schabath M., Wu X., Vassilopoulou-Sellin R., et al. Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin Cancer Res 10 (2004) 113-123
53. Blackman J., Coogan P., Rosenberg L., et al. Estrogen replacement therapy and risk of lung cancer. Pharmacoepidemiol Drug Saf 11 (2002) 561-567
54. Ramnath N., Reid M., and Loewen G. Hormone replacement therapy and reduced risk of lung cancer in post-menopausal women. Lung Cancer 49 suppl 2 (2005) Abstr O-052
55. Thomsen J., Wang X., Hines R., et al. Restoration of aryl hydrocarbon (Ah) responsiveness in MDA-MB-231 human breast cancer cells by transient expression of the estrogen receptors. Carcinogenesis 15 (1994) 933-937
56. Wormke M., Stoner M., Saville B., et al. The aryl hydrocarbon receptor mediates degradation of estrogen receptor alpha through activation of proteasomes. Mol Cell Biol 23 (2003) 1843-1855
57. Tansavatdi K., McClain B., and Herrington D. The effects of smoking on estradiol metabolism. Minerva Ginecol 56 (2005) 105-114
58. Tanko L., and Christiansen C. An update on the antiestrogenic effect of smoking: a literature review with the implications for researchers and practitioners. Menopause 11 (2004) 104-109
59. Miller W. Biology of aromatase inhibitors: pharmacology/endocrinology within the breast. Endocr Relat Cancer 6 (1999) 187-195
60. Nabholtz J., Buzdar A., Pollak M., et al., on behalf of the Arimidex Study Group. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 18 (2000) 3758-3767
61. Patel J., Gray R., Stewart J., et al. Tamoxifen does not reduce the risk of lung cancer in women. J Clin Oncol 23 suppl 16 (2005) abstr 7212
62. Coombes R., Hall E., Gibson L., et al. A randomized trial of exemestane after two or three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 (2004) 1081-1092
63. Revelli A., Massobrio M., and Tesarik J. Nongenomic actions of steroid hormones in reproductive tissues. Endocr Rev 19 (1998) 3-17
64. Norman A., Mizwicki M., and Norman D. Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat Rev Drug Discov 3 (2004) 27-41
65. Falkinstein E., and Wehling M. Nongenomically initiated steroid actions. Eur J Clin Invest 30 suppl 3 (2000) 51-54
66. Razandi M., Pedram A., Greene G., et al. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ER α and ER β expressed in Chinese hamster ovary cells. Mol Endocrinol 13 (1999) 307-319
67. Nadal A., Ropero A., Fuentes E., et al. The plasma membrane estrogen receptors: nuclear or unclear?. Trends Pharmacol Sci 22 (2001) 597-599
68. Thomas P., Pang Y., Filardo E., et al. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 146 (2005) 624-632
69. Revanker C., Cimino D., Sklar L., et al. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307 (2005) 1625-1630
70. Song R., McPherson R., Adam L., et al. Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol Endocrinol 16 (2002) 116-127
71. Yarden R., Wilson M., and Chrysogelos S. Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth. J Cell Biochem Suppl 36 (2001) 232-246
72. Razandi M., Pedram A., Park S., et al. Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem 278 (2003) 2701-2712
73. Kato S., Endoh H., Masuhiro Y., et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270 (1995) 1491-1494
74. Di Nunno L., Larsson L., Rinehart J., and Beissner R. Estrogen and progesterone receptors in non-small cell lung cancer in 248 consecutive patients who underwent surgical resection. Arch Pathol Lab Med 124 (2000) 1467-1470
75. Ishibashi H., Suzuki T., Suzuki S., et al. Progesterone receptor in non-small cell lung cancer: a potent prognostic factor and possible target for endocrine therapy. Cancer Res 65 (2005) 6450-6458
76. Croxtall J., and Flower R. Lipocortin 1 mediates dexamethasone-induced growth arrest of the A549 lung adenocarcinoma cell line. Proc Natl Acad Sci USA 89 (1992) 3571-3575
77. Balana M., Lupu R., Labriola L., et al. Interactions between progestins and heregulin (HRG) signaling pathways: HRG acts as mediator of progestins proliferative effects in mouse mammary adenocarcinomas. Oncogene 18 (1999) 6370-6379
78. Chu I., Blackwell K., Chen S., and Slingerland J. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 65 (2005) 18-25
79. Kurokawa H., and Arteaga C. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. Clin Cancer Res 7 suppl 12 (2001) 4436S-4442S
80. Chen Y., Perng R., Yang K., et al. Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy. Lung Cancer 29 (2000) 139-146
81. Yang C., Cheng A., Yeh K., et al. High dose tamoxifen plus cisplatin and etoposide in the treatment of patients with advanced, inoperable non small cell lung carcinoma. Cancer 86 (1999) 415-420
82. Dubey S., Siegfried J., Stabile L., et al. Combination therapy with gefitinib and fulvestrant (G/F) for women with non-small cell lung cancer (NSCLC). Lung Cancer 49 suppl 2 (2005) abstr PD-071